References
- Holliday SM, Benfield venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs 1995; 4:280–282.
- Johnson EM, Whyte E, Mulsant BH, Pollock BG, Weber E, Begley AE, Reynolds CF. Cardiovascular changes associated with venlafaxine in the treatment of late life depression. Am J Geriatr Psychiatry 2006; 14:796–802.
- Shamliyan TA, Kane RL, Wyman J, Wilt TJ. Systematic review: randomized, controlled trials of nonsurgical treatments for urinary incontinence in women. Ann Intern Med 20081; 48: 459–473.
- Mariappan P, Ballantyne Z, N'Dow JM, Alhasso AA. Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults. Cochrane Database Syst Rev 2005; 3:CD004742. [Cited 26 August 2010] Available from URL http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004742/frame.html
- Inghilleri M, Conte A, Frasca V, Bettolo CM, Iacovelli E, Aragona M, Carbone A, Prencipe M. Venlafaxine and bladder function. Clin Neuropharmacol 2005; 28:270–273.
- Mant A, Rendle VA, Mitchell PB, Montgomery WS, McManus PR, Hickie IB. Making new choices about antidepressants in Australia: the long view 19752002. Med J Aust 2004; 181:S21–24.
- Jost W, Marsalek P. Duloxetine: mechanism of action at the lower urinary tract and Onuf's nucleus. Clin Auton Res 2004; 14:220–27.
- Wyeth Pharmaceuticals Inc. Effexor Medicines Data Sheet. 2006. [Cited 28 July 2010.] Available from URL http://www.wyeth.com/content/showlabeling.asp?id=99.